title: Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
abstract: Cdc25C is a cell cycle protein of the dual specificity phosphatase family essential for activating the cdk1/Cyclin B1 complex in cells entering into mitosis. Since altered cell cycle is a hallmark of human cancers, we investigated androgen regulation of Cdc25C protein in human prostate cancer (PCa) cells, including androgen-sensitive (AS) LNCaP C-33 cells and androgen-independent (AI) LNCaP C-81 as well as PC-3 cells. In the regular culture condition containing fetal bovine serum (FBS), Cdc25C protein levels were similar in these PCa cells. In a steroid-reduced condition, Cdc25C protein was greatly decreased in AS C-33 cells but not AI C-81 or PC-3 cells. In androgen-treated C-33 cells, the Cdc25C protein level was greatly elevated, following a dose- and a time-dependent manner, correlating with increased cell proliferation. This androgen effect was blocked by Casodex, an androgen receptor blocker. Nevertheless, epidermal growth factor (EGF), a growth stimulator of PCa cells, could only increase Cdc25C protein level by about 1.5-fold. Altered expression of Cdc25C in C-33 cells and PC-3 cells by cDNA and/or shRNA transfection is associated with the corresponding changes of cell growth and Cyclin B1 protein level. Actinomycin D and cycloheximide could only partially block androgen-induced Cdc25C protein level. Treatments with both proteasomal and lysosomal inhibitors resulted in elevated Cdc25C protein levels. Immunoprecipitation revealed that androgens reduced the ubiquitination of Cdc25C proteins. These results show for the first time that Cdc25C protein plays a role in regulating PCa cell growth, and androgen treatments, but not EGF, greatly increase Cdc25C protein levels in AS PCa cells, which is in part by decreasing its degradation. These results can lead to advanced PCa therapy via up-regulating the degradation pathways of Cdc25C protein.
authors: Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
authors: Yu-Wei
authors: YW
authors: Chou
authors: Li
authors: L
authors: Zhang
authors: Sakthivel
authors: S
authors: Muniyan
authors: Humera
authors: H
authors: Ahmad
authors: Satyendra
authors: S
authors: Kumar
authors: Syed Mahfuzul
authors: SM
authors: Alam
authors: Ming-Fong
authors: MF
authors: Lin
mesh_terms: D000728:Androgens / Q000494:pharmacology*; D018797:Cell Cycle Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D013196:Dihydrotestosterone / Q000494:pharmacology; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008247:Lysosomes / Q000187:drug effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000201:enzymology; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects*; D061988:Proteasome Inhibitors / Q000494:pharmacology; D011944:Receptors, Androgen / Q000187:drug effects; D059467:Transcriptome; D015854:Up-Regulation; D020687:cdc25 Phosphatases / Q000096:biosynthesis* / Q000378:metabolism
chemical_list: C410798:AR protein, human; D000728:Androgens; D018797:Cell Cycle Proteins; D007976:Leupeptins; D061988:Proteasome Inhibitors; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D020687:cdc25 Phosphatases; D046988:Proteasome Endopeptidase Complex; D007930:Leucine; C032854:leupeptin; C108192:aloxistatin
references: Mol Cell Biol. 2001 Jun;21(12):3853-61
references: 11359894
references: Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5
references: 11842186
references: Biochem Biophys Res Commun. 2008 Jun 6;370(3):483-8
references: 18384749
references: Cancer Lett. 2011 Dec 8;311(2):177-86
references: 21862211
references: Nature. 1998 Oct 1;395(6701):507-10
references: 9774107
references: Free Radic Biol Med. 2012 Jul 1;53(1):95-108
references: 22561705
references: Mol Biol Cell. 2003 Jul;14(7):2984-98
references: 12857880
references: Cancer Cell. 2003 May;3(5):421-9
references: 12781359
references: Science. 1997 Sep 5;277(5331):1501-5
references: 9278512
references: J Biol Chem. 1998 Mar 6;273(10):5939-47
references: 9488733
references: Oncogene. 2009 Aug 20;28(33):2925-39
references: 19561645
references: Cell. 1991 Dec 20;67(6):1181-94
references: 1836978
references: Oncogene. 2003 Feb 6;22(5):734-9
references: 12569365
references: Nat Genet. 2002 Apr;30(4):446-9
references: 11912493
references: Nat Rev Cancer. 2009 Mar;9(3):153-66
references: 19238148
references: New Biol. 1991 Oct;3(10):959-68
references: 1662986
references: Nat Cell Biol. 2003 May;5(5):461-6
references: 12717448
references: Prostate. 2007 Apr 1;67(5):557-71
references: 17221842
references: J Biol Chem. 2010 Jul 30;285(31):23598-606
references: 20498373
references: In Vivo. 2001 Mar-Apr;15(2):163-8
references: 11317522
references: Cell Prolif. 1991 Sep;24(5):447-59
references: 1657218
references: Oncogene. 2000 May 18;19(22):2664-77
references: 10851066
references: Cancer Res. 2003 Oct 1;63(19):6195-9
references: 14559803
references: Cell Biol Int. 2000;24(10):681-9
references: 11023645
references: PLoS One. 2011 Jan 14;6(1):e15942
references: 21264241
references: Science. 1997 Sep 5;277(5331):1497-501
references: 9278511
references: Cell Cycle. 2004 Jun;3(6):733-7
references: 15136768
references: Cancer Res. 1983 Apr;43(4):1809-18
references: 6831420
references: Anticancer Agents Med Chem. 2008 Dec;8(8):832-6
references: 19075565
references: Cell Cycle. 2006 Apr;5(7):709-13
references: 16582636
references: Int J Cancer. 2004 Feb 20;108(5):672-8
references: 14696093
references: Nat Rev Cancer. 2007 Jul;7(7):495-507
references: 17568790
references: J Biol Chem. 1998 Aug 21;273(34):22096-104
references: 9705354
references: Int J Biochem Cell Biol. 2007;39(9):1707-13
references: 17548228
references: Oncogene. 2008 Aug 28;27(37):5057-68
references: 18504439
references: Invest Urol. 1979 Jul;17(1):16-23
references: 447482
references: Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20
references: 18782595
references: Endocr Relat Cancer. 2005 Dec;12(4):805-22
references: 16322323
references: Cell Cycle. 2006 Apr;5(7):759-65
references: 16582626
references: Lab Invest. 2001 Apr;81(4):465-73
references: 11304565
references: Int J Cancer. 1978 Mar 15;21(3):274-81
references: 631930
references: Mol Cell Biol. 2001 Dec;21(23):8056-67
references: 11689696
references: Science. 1998 Dec 4;282(5395):1893-7
references: 9836640
references: Clin Cancer Res. 2005 Jul 1;11(13):4701-6
references: 16000564
references: J Urol. 2001 Nov;166(5):1943-50
references: 11586265
references: Mol Cell Biol. 1986 Dec;6(12):4753-7
references: 3796616
references: Oncology. 2003;65(2):159-66
references: 12931023
references: Cancer Res. 2007 Jul 15;67(14):6605-11
references: 17638870
references: Oncogene. 2002 Mar 7;21(11):1717-26
references: 11896603
references: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500
references: 9815652
references: Curr Opin Cell Biol. 2006 Apr;18(2):185-91
references: 16488126
references: J Biol Chem. 2000 Feb 25;275(8):5600-5
references: 10681541
references: Prostate. 2002 Mar 1;50(4):222-35
references: 11870800
references: Cell. 2007 Mar 23;128(6):1119-32
references: 17382881
references: Oncogene. 2004 Apr 15;23(17):3048-58
references: 14990987
references: Cancer Res. 1992 Sep 1;52(17):4600-7
references: 1380886
references: Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32
references: 11413462